L-743,872
PreclinicalSmall molecule
Merck & Co.L-743,872 is one of 13 small molecule programs targeting Esophagitis. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Esophagitis
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Dexilant
TakedaApproved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Aciphex
Akero TherapeuticsApproved
Flovent
PParatek Pharmaceuticals Inc
Approved
Protonix
WWyeth-Lederle Vaccines
Approved
Pulmicort
SSalix
Approved
Alka-Seltzer
AAbbott
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Rabeprazole ER
EisaiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-743,872. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company